Determination of 5-fluorouracil and dihydrofluorouracil levels by using a liquid chromatography-tandem mass spectrometry method for evaluation of dihydropyrimidine dehydrogenase enzyme activity
CANCER CHEMOTHERAPY AND PHARMACOLOGY, cilt.68, sa.2, ss.525-529, 2011 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 68 Sayı: 2
- Basım Tarihi: 2011
- Doi Numarası: 10.1007/s00280-010-1528-1
- Dergi Adı: CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
- Sayfa Sayıları: ss.525-529
- Anahtar Kelimeler: Dihydropyrimidine dehydrogenase, 5-Fluorouracil, Dihydrofluorouracil, LC-MS/MS, BLOOD MONONUCLEAR-CELLS, CANCER-PATIENTS, DPD DEFICIENCY, TOXICITY, IDENTIFICATION, MUTATIONS, INFUSION, PATIENT, LIVER, COLON
- Acıbadem Mehmet Ali Aydınlar Üniversitesi Adresli: Hayır
Özet
Purpose 5-Fluorouracil (5-FU), acting as a pyrimidine antagonist, is a major chemotherapy drug used for the treatment of tumors such as gastrointestinal, breast, ovary, and head and neck cancers. The key and rate-limiting enzyme in 5-FU catabolism is dihydropyrimidine dehydrogenase (DHPDH), whose partial or complete deficiency exposes to a severe 5-FU toxicity in patients. The determination of DHPDH activity in patients before the treatment and setting up a personalized therapy for each patient receiving the drug can help us to prevent the possible risk of toxicity.